Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
CytomX revenue
CytomX's revenue is $138.1 million.
What is CytomX's revenue?
- CytomX's revenue growth from 2014 to 2024 is 2,620.17%.
- CytomX has 139 employees, and the revenue per employee ratio is $993,546.
- CytomX's peak quarterly revenue was $38.1M in 2024(q4).
- CytomX peak revenue was $138.1M in 2024.
- CytomX annual revenue for 2023 was 101.2M, 90.38% growth from 2022.
- CytomX annual revenue for 2024 was 138.1M, 36.45% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
CytomX historical revenue
CytomX's peak revenue was $138.1M in 2024. The peak quarterly revenue was $38.1M in 2024(q4).
CytomX's revenue increased from $5.1m in 2014 to $138.1M currently. That's a 2,620.17% change in annual revenue.
CytomX annual revenue
CytomX annual revenue over time
| Fiscal year / year | CytomX revenue |
|---|---|
| 2014 | $5.1M |
| 2015 | $7.7M |
| 2016 | $15.0M |
| 2017 | $71.6M |
| 2018 | $59.5M |
| 2019 | $57.5M |
| 2020 | $100.4M |
| 2021 | $37.3M |
| 2022 | $53.2M |
| 2023 | $101.2M |
| 2024 | $138.1M |
Rate CytomX's financial transparency
CytomX annual growth
CytomX saw the greatest revenue growth in 2017, when revenue increased by 376.12%.
CytomX had the lowest revenue growth in 2021, when revenue changed by -62.82%.
CytomX annual growth rate over time
| Year | CytomX growth |
|---|---|
| 2015 | 52%↑ |
| 2016 | 95%↑ |
| 2017 | 376%↑ |
| 2018 | -17%↓ |
| 2019 | -3%↓ |
| 2020 | 75%↑ |
| 2021 | -63%↓ |
| 2022 | 42%↑ |
| 2023 | 90%↑ |
| 2024 | 36%↑ |
CytomX jobs nearby
Do you work at CytomX?
Is CytomX transparent about its revenue structure?
CytomX financial information
| CEO | Sean A. McCarthy D. Phil |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 139 |
| Date Founded | 2008 |
| Headquarters | South San Francisco, California |
| Number of Locations | 7 |
| Revenue | $138.1M |
| Net Income | -$99,317,000 |
| Tax Rate | 0.0% |
| Total Assets | $260,890,000 |
| Ticker | CTMX |
CytomX jobs you might like
CytomX financing
CytomX received early financing of $2.5M on 2010-03-03.
| Series | Round size | Date |
|---|---|---|
| Convertible Note | $2.5M | 03/2010 |
| Series B | $30M | 09/2010 |
| Series B | $11M | 07/2012 |
| Series B | $1.4M | 04/2014 |
| Series C | $20M | 01/2015 |
| Series D | $70M | 06/2015 |
| Post Ipo Equity | $116.9M | 07/2018 |
| Post Ipo Equity | $93.6M | 01/2021 |
CytomX investors
| Investors | Security type |
|---|---|
| Mike Panesis | Convertible Note |
| Third Rock Ventures | Series B |
| Roche Venture Fund | Series B |
| Canaan Partners | Series B |
| Third Rock Ventures | Series B |
| Canaan Partners | Series C |
| Pfizer Venture Investments | Series C |
| Third Rock Ventures | Series C |
| Roche Venture Fund | Series C |
| Redmile Group | Series D |
| Tekla Capital Management | Series D |
| Wellington Management | Series D |
| Venrock | Series D |
| Deerfield | Series D |
| Cormorant Asset Management | Series D |
| Perceptive Advisors | Series D |
| Casdin Capital | Series D |
CytomX competitors
CytomX's top competitor, Ardelyx, earned an annual revenue of $333.6M.
CytomX's smallest competitor is Synlogic with revenue of $8.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| MacroGenics | - | $150.0M | 307 | - |
| Ardelyx | - | $333.6M | 86 | - |
| Synlogic | - | $8,000 | 74 | - |
| Syros Pharmaceuticals | - | $9.9M | 124 | - |
| Ophthotech | - | $210.0M | 58 | - |
| Omeros | - | $29.9M | 265 | - |
| Genocea | - | - | 59 | - |
| CRISPR Therapeutics | - | $37.3M | 304 | - |
| Blueprint Medicines | - | $508.8M | 495 | - |
| AnaptysBio | - | $91.3M | 78 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
CytomX highest paying jobs
Zippia gives an in-depth look into the details of CytomX, including salaries, political affiliations, employee data, and more, in order to inform job seekers about CytomX. The employee data is based on information from people who have self-reported their past or current employments at CytomX. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by CytomX. The data presented on this page does not represent the view of CytomX and its employees or that of Zippia.
CytomX may also be known as or be related to CYTOMX THERAPEUTICS INC., CytomX, CytomX Therapeutics, CytomX Therapeutics Inc, CytomX Therapeutics, Inc., Cytomx Therapeutics and Cytomx Therapeutics, Inc.